

**PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES**  
**July 9, 2013**

The meeting was called to order at approximately 2:09 p.m. on Tuesday, July 9, 2013.

Committee members present: Melissa Bowlby, PA-C; James Fry, P.A.-C; Sean Stiltner, D.O.; Anita Steinbergh, D.O.; Robert Flora, M.D.; Theresa Hoffmann, Pham. D.; and Eric Luckage.

Staff members present: Sallie Debolt, and Cathy Hacker

Guests: Beth Adamson, Executive Director, OAPA.

***I. Review of the June 11, 2013 minutes.***

Ms. Bowlby began the meeting by requesting the approval of the minutes.

Dr. Steinbergh noted that on page 3 of the minutes under the review of the draft model supervisory plan for orthopaedic practices that the second reference to board eligible should be board qualified.

Dr. Steinbergh moved to approve the minutes from the June 11, 2013 PAPC meeting with the above amendment. Dr. Flora seconded the motion. All members voted aye. The motion carried.

***II. Formulary Review***

The meeting began with the discussion of Invokana which is a new drug to treat type 2 diabetes. Ms. Hoffman stated that it is a 3<sup>rd</sup> line diabetic medication that is used to lower blood sugar. She stated that this is a sodium glucose co transporter/inhibitor. It causes the body to secrete glucose through the urine at a higher rate. It was further noted that one of the side effects of this medication is fungal urinary tract infections and that the prescribers should be aware of this side effect and be looking for fungal infections as opposed to bacterial infections. It was the consensus of the committee that this medication should be in the physician initiated category until the medical community becomes more aware of its uses and side effects.

The committee discussed the medication Linzess. It was noted that this medication is a laxative and already on the formulary as CTP may prescribe. No action was needed.

The committee then discussed the medication Qsymia it was noted that this medication is an anorexiant and already in the formulary as CTP may not prescribe. No action was taken.

The committee reviewed the language in the Scheduled section of the formulary and removed the reference to Division (A) of 4730.411 ORC as it was inserted in error.

Dr. Steinbergh moved to approve the above changes to the formulary. Dr. Stiltner seconded the motion. All members voted aye. The motion carried.

The committee discussed the need for items for consideration at the meetings must be received at least 72 hours in advance of the meeting for discussion. This will give the members time to review the material for discussion. Mr. Luckage felt that outside parties with question should be allowed to ask questions so long as no vote on the question is

needed. If the committee is not able to answer the question immediately it could be brought back to them the following meeting.

Ms. Hoffmann provided a proposed new format to the formulary for the members to review. This format would be a more user friendly document and would allow the committee to add various drugs to different areas of the formulary for easier use.

Dr. Flora moved to adopt the new format for review. Dr. Stiltner seconded the motion. All members voted aye. The motion carried.

Mr. Luckage moved to add as a monthly item to the agenda “new business matters”. Mr. Fry seconded the motion. All members voted aye, the motion carried.

### **III. Review special services requests**

The committee reviewed the special services request from **Bruce Rank, MD** requesting approval of: Sclerotherapy.

It was noted during discussion that this type of application has been approved in the past with the same or similar levels of training, education and supervision. Dr. Rank has submitted a plan with a higher level of supervision than those that have been previously approved.

Dr. Steinbergh moved to approve this application. Mr. Fry seconded the motion. All members voted aye. The motion carried.

### **IV. Review rules**

The committee then moved on to the rules review as required by the implementation of HB 284 and the five year rule review process.

Ms. Debolt explained to the committee that since PA’s now have the ability to Prescribe Schedule II medications she felt that we needed to add the PA rules to section 4730-1-07 OAC in order to tie in the restrictions for prescribing controlled substances to family members to the PA’s and adds the OARRS rules to the PA’s as well.

Dr. Flora moved to approve this rule for filing. Dr. Stiltner seconded the motion. All members voted aye. The motion carried

The committee noted that 4730-2-06 appendix A needed to be rescinded as the new legislation removed the formulary from the rule. An amendment was made to 4730-2-06(A) to remove the prohibition of PA’s prescribing schedule II’s.

The committee discussed 4730-2-06(H) and the need for it to be revised to remove language and added to the formulary. They were unable to come up with suitable language and referred the matter the PA committee for their comments.

Dr. Steinbergh moved to approve the removal of the appendix, and the prohibition in paragraph A of 4730-2-06 and to refer paragraph H to group 2 for their comments. Dr. Stiltner seconded the motion. All members voted aye. The motion carried.

**V.***Ethics training*

Ms. Debolt gave the members information on obtaining their ethics training by the end of the year.

The Physician Assistant Policy Committee meeting was adjourned by Ms. Bowlby at approximately 3:40 p.m. on Tuesday, July 9, 2013.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on July 9, 2013.

---

Melissa Bowlby, PA-C  
Chair, PAPC

Copies of documents and/or materials referenced in the minutes of the Physician Assistant Policy Committee meeting are available at the Board offices.